The maker of a promising ovarian cancer drug said, Friday, that he stopped enrolling women in a study because several patients developed gastrointestinal holes.
More than 10% of participants in the study developed gastrointestinal holes.
( z1 develop :ARG1 ( z2 person :ARG1-of ( z3 include :ARG2 ( z4 person :ARG0-of ( z5 participate :ARG1 ( z6 study ) ) ) :ARG3 ( z7 more-than :op ( z8 percentage-entity :value 10 ) ) ) ) :ARG2 ( z9 hole :mod ( z10 gut ) ) )